A decision on the purchase of blackout curtains to be used at U.S. Bank Stadium during the 2019 men's college basketball tournament is now set for May 3, less than three weeks from now ("Stadium officials delay their darkening solution by one month," April 13). Although public funds will be used for this costly expense, neither the chair nor the acting executive director of the Minnesota Sports Facilities Authority will "reveal the number of bids that have come in or the potential cost." Why not? Is such secrecy consistent with accountability in the expenditure of public dollars?
Michael W. McNabb, Lakeville
ONLINE PRIVACY
Some say it's naive. But if we don't pursue it now, when?
While some people (Readers Write, April 12) believe that any expectation of data privacy is naive in today's world, I think now is the time to challenge that view and set strong standards for protecting our personal information online.
Every few months it seems we learn about another massive data scandal like what Cambridge Analytica did with Facebook. Why must we accept these breaches as an unavoidable fact of modern life? On the contrary, we should be able to expect privacy settings on Facebook and other social-networking sites to mean something when it comes to access by their third-party apps and advertising partners.
U.S. Sen. Amy Klobuchar was right in hearings with Facebook CEO Mark Zuckerberg to focus attention on protecting our online data and holding companies accountable for their use and dissemination of it. It is not naive to expect companies to handle our information responsibly so they do not sell or expose it (or that of our friends) without our permission.
Who benefits from throwing up our hands and accepting the status quo? Not you and me — it's tech companies, advertisers and political operations, among others. Klobuchar understands this. We have a right to privacy — even when we're online.
Susan Reinking, Eden Prairie
COMPETING IN BIOTECH
Cost of securing intellectual property is significant obstacle
An April 9 Business Forum article ("Life sciences merit an all-out effort") advocates for public support and investment to ensure that the state of Minnesota can successfully compete with biotechnology meccas in California and Boston. As a veteran biotechnology scientist and entrepreneur, I cannot agree more. However, I find it interesting that the patent lawyer authoring this article ignored a key factor that could really boost our struggling biotech industry: intellectual property legal support that does not bleed the founders of a biotechnology company dry.
As far back as 2011, the projected cost for filing a patent application in the technology industries was estimated at $60,000 (https://tinyurl.com/tech-patent-cost). Given the fact that most biotechnology companies have multiple patent applications that need to be filed, prosecuted and protected, IP costs rapidly become the biggest expense for an aspiring biotech entrepreneur. Government grants can often be tapped to cover the costs of doing the research and science, but the National Institutes of Health does not allow these nondilutive grants to be used for IP licensing and patent prosecution costs.
What Minnesota needs are IP lawyers and university technology transfer offices willing to support company portfolios with delayed compensation in exchange for equity returns. Equity has the potential for a much higher payoff to the technology transfer offices and IP law firms, while making sure these integral aspects of a successful biotechnology business are playing with skin in the game rather than just swallowing up financial resources.